1. Introduction {#sec1}
===============

Lipid oxidation is an important process in many different biological systems. In a food context, lipid oxidation is one of the major causes of food deterioration, as it may lead to off-flavours, changes in colour and texture and also decreased nutritional value of food products ([@bib11]). Lipid oxidation can proceed in either a non-enzymatic or an enzymatic fashion. Lipoxygenases (LOX) constitute a family of non-haem iron-containing enzymes that catalyst oxidation of fatty acids and are widely distributed in plants and animals ([@bib22]; [@bib30]; [@bib23]). In plants, the substrate is mainly linoleic acid (LA) (C18:2, n-6) and α-linolenic acid (ALA) (C18:3, n-3), whereas in mammals it is arachidonic acid (AA) (C20:4, n-6). In mammals vegetable LA can be transformed to AA though enzyme mediated elongation and desaturation reactions. The same reactions also transform ALA to eicosapentaenoic acid (EPA, C20:5, n-3) and docosahexaenoic acid (DHA, C22:6, n-3). Lipid oxidation can be a problem in living systems, by altering the function of membranes and lipoprotein particles ([@bib30]). In mammalian cells, LOX catalyse the initial step in the conversion of AA to the hydroperoxide, 5-hydroperoxy-6,8,11,14-eicostatetraenoic acid, and are thereby key enzymes in the biosynthesis of a variety of bio-regulatory compounds such as leukotrienes ([@bib38]; [@bib20]; [@bib41]). Leukotrienes are considered to be potent mediators of pro-inflammatory reactions. LOX enzymes are also associated to biosynthesis of compounds which may promote termination of acute inflammation reactions, and thereby function as anti-inflammatory agents. Such compounds are for example lipoxins, which are biosynthesised via oxygenation of AA, and resolvins, biosynthesised though oxygenation of the ω-3 fatty acids EPA and DHA ([@bib40]; [@bib44]; [@bib30]; [@bib41]). Acute inflammation is a protective process. However, overbalance of pro-inflammatory vs anti-inflammatory agents over time may result in a variety of chronic inflammatory diseases, such as arthritis, bronchial asthma, and cardiovascular diseases ([@bib54]; [@bib38]; [@bib9]; [@bib20]; [@bib30]; [@bib4]). Therefore, inhibition of the pro-inflammatory LOX pathway is suggested to be interesting for prevention of these disesases. Many of the LOX inhibitors are found among the class of phenolic compounds, which have radical scavenging and/or iron chelating properties, and among fatty acid analogues ([@bib54]; [@bib46], [@bib47]; [@bib38]; [@bib9]).

Avenanthramides (AVAs) belong to a group of phenols comprising anthranilic and cinnamic acid derivatives ([Figure 1](#fig1){ref-type="fig"}a; [Table 1](#tbl1){ref-type="table"}). Among cereals, AVAs are found only in oats and so far 15 compounds have been identified ([@bib14]; [@bib32]; [@bib2]; [@bib10]; [@bib25]; [@bib42]; [@bib39]; [@bib3]). The three most abundant AVAs in oat groats are **2p**, **2f** and **2c,** the **2** indicating 5-hydroxyanthranilic acid (as opposed to **1** for anthranilic acid, **3** for 5-hydroxy-4-methoxyanthranilic acid, **4** for 4-hydroxy anthranilic acids and **5** for 4,5-dihydroxyanthranilic acid), and the **p, f** and **c** indicating the cinnamic acids *p-*coumaric, ferulic and caffeic acid, respectively ([@bib2]; [@bib16]; [@bib13]; [@bib25]; [@bib42]; [@bib3]). Other AVAs with cinnamic acids replaced by the corresponding avenalumic acids (5-phenyl-penta-2,4 dienoic) are also present in oats ([@bib13]; [@bib10]; [@bib25]; [@bib39]; [@bib3]). Sinapic acid (**s**) is found in oats, but no AVAs derived from this acid have been found in oat plant ([@bib2]; [@bib10]).Figure 1Structures of compounds used in the experiments: a) avenanthramides (**1s**, **2s** and **3s** are not found in oats), Tranilast®, and cinnamic acids (see [Table 1](#tbl1){ref-type="table"} for the substitution pattern of the molecular skeletons) and b) *trans-*resveratrol.Figure 1Table 1Structures of compounds used in the experiments (refers to [Figure 1](#fig1){ref-type="fig"}a).Table 1R1R2R3R4R5Avenanthramide[1](#tbl1fn1){ref-type="table-fn"}**1p**HHHOHH**2p**OHHHOHH**3p**OHOCH~3~HOHH**1f**HHOCH~3~OHH**2f**OHHOCH~3~OHH**3f**OHOCH~3~OCH~3~OHH**1c**HHOHOHH**2c**OHHOHOHH**3c**OHOCH~3~OHOHH**1s**HHOCH~3~OHOCH~3~**2s**OHHOCH~3~OHOCH~3~**3s**OHOCH~3~OCH~3~OHOCH~3~Tranilast®HHOCH~3~OCH~3~HCinnamic acid**p**HOHH**f**OCH~3~OHH**c**OHOHH**s**OCH~3~OHOCH~3~[^1]

Consumption of oats has been linked to a decreased risk of several chronic diseases and it has been suggested that AVAs contribute to the protective effects ([@bib33]; [@bib52]). In *in vitro* studies, AVAs have been characterised as antioxidants with a clear structure-activity relationship ([@bib14]; [@bib2]; [@bib16]; [@bib31]; [@bib25]). They have also been shown to be bioavailable ([@bib56]) and to exert antioxidant activity *in vivo* ([@bib26]; [@bib8], [@bib7]; [@bib27]). Furthermore, they have been found to exhibit anti-inflammatory, anti-proliferative and anti-itch activities *in vitro* and *in vivo* ([@bib35], [@bib36]; [@bib50]; [@bib27]; [@bib43]; [@bib21]; [@bib45]). In a food context, AVAs have been shown to be correlated to the fresh oat taste of oat products ([@bib34]).

In this study it is hypothesized that AVAs partly protect oat foods from rancidity development through inhibition of LOX activity. Furthermore, a hypothesis is that AVAs may inhibit LOX and/or cyclooxygenase (COX-2) enzymes in mammals and thereby decrease the production of pro-inflammatory compounds, such as leukotrienes and prostaglandins. An AVA-enriched oat extract has been shown to inhibit cyclooxygenase (COX-2) activity and pro-inflammatory prostaglandin production from AA in mouse macrophages ([@bib19]). Furthermore, a butanolic fraction of oat groats has been found to have anti-platelet activities mediated though inhibition of the COX and LOX pathways ([@bib1]). The authors of the latter study did not speculate about the possible compounds involved, but a high amount of AVAs is probably present in a butanol extract, since methanol and ethanol are good extracting solvents for AVAs ([@bib13]).

The aim of the present work was to investigate whether pure AVAs and their corresponding free cinnamic acids ([Figure 1](#fig1){ref-type="fig"}a; [Table 1](#tbl1){ref-type="table"}), have LOX inhibitor activity *in vitro*. A further aim was to establish a structure-inhibition activity relationship. *Trans*-resveratrol ([Fig. 1](#fig1){ref-type="fig"}b), a phenolic stilbene known to possess LOX inhibitor activity ([@bib17]; [@bib6]), was used as a positive control. Tranilast® ([Figure 1](#fig1){ref-type="fig"}a; [Table 1](#tbl1){ref-type="table"}), a known non-phenolic drug with anti-inflammatory properties ([@bib37]; [@bib12]) and with remarkable chemical similarities to the AVAs was used as a negative control ([@bib28]).

2. Materials and methods {#sec2}
========================

2.1. Chemicals {#sec2.1}
--------------

Lipoxygenase, LOX 1 from soybean, (EC 1.13.11.12), was purchased from SIGMA Chemicals Co. (St. Louis, MO, USA), linoleic acid from Calbiochem® (U.S and Canada), sinapic acid from Fluka Chemie AG (Buchs SG, Switzerland) and ferulic-, caffeic- and *p*-coumaric acid from SIGMA Chemicals Co. (St. Louis, MO, USA). All AVAs were synthesised according to [@bib2] (**1**- and **2**-series) or [@bib16] (**3**-series). All other chemicals used were *pro analysi* and were used without further purification.

2.2. HPLC analysis {#sec2.2}
------------------

Reverse-phase high performance liquid chromatography (RP-HPLC) analysis was performed with an HP series 1100 instrument (Hewlett Packard, Waldbronn, Germany) equipped with diode array detector (DAD) and a HP ODS Hypersil column (5 μm, 125 mm × 4 mm). The isocratic mobile phase was acetonitrile:0.01M phosphate buffer (pH 2.8) containing 5% acetonitrile (70:30). Sample size injected was 10 μL and the flow rate was 1 mL/min. Products of LOX activity were detected at 234 nm ([@bib53]). Peaks were identified from retention times ([Figure 2](#fig2){ref-type="fig"}) and UV-spectra, and were manually integrated using the software HP ChemStation Version 05.01.Figure 2Reverse-phase chromatogram of lipoxygenase products detected at 234 nm of a) an active lipoxygenase enzyme and b) an inactivated lipoxygenase enzyme.Figure 2

2.3. Preparation of solutions {#sec2.3}
-----------------------------

Enzyme solution was prepared by thoroughly mixing 4 μL enzyme with 20 mL 0.1 M borate buffer (Na~3~(BO)~3~/HCl), pH 9. Substrate solution was prepared by dispersing 15 μL linoleic acid in 60 mL 0.1 M borate buffer (pH 9) containing 15 μL Tween 20, shaking thoroughly and then sonicating for 1 min. AVAs, Tranilast®, *trans*-resveratrol and the cinnamic acid derivatives were prepared as 9 mM stock-solutions in ethanol/borate buffer (15/85). All solutions were used promptly to avoid autoxidation and degradation of enzyme.

2.4. LOX assay {#sec2.4}
--------------

Enzyme solution (100 μL) was mixed with 200 μL of a stock-solution of the test compound and the mixture was incubated for 10 min. Then 2.7 mL of linoleic acid solution were added and the mixture was vortexed and incubated in a 30 °C water bath for 30 min. The enzymatic reaction was stopped by adding 100 μL of concentrated hydrochloric acid. The reaction mixture was extracted with 3.0 mL of ethyl acetate. A 2 mL sample of the organic phase was collected and evaporated to dryness in a centrifuge evaporator. The solid residue was dissolved in 200 μL of methanol and analysed by HPLC. As a control sample, ethanol/buffer solution without added test compound was used. In addition, a control in which hydrochloric acid was added to the enzyme solution prior to linoleic acid, in order to inactivate the enzyme, was included ([Figure 2](#fig2){ref-type="fig"}).

In order to compare inhibition of the different compounds, the same molar concentration (0.6 mM) in the final test solution was used in all tests. In a pre-test it was found that 0.6 mM was appropriate for ca 50% inhibition of the enzyme activity when using caffeic acid as the inhibitor.

For practical reasons, the controls and four test compounds were analysed in each experiment. Seven experiments (A-G) were performed to study the structure-LOX-inhibition activity relationships for AVAs/cinnamic acids. In the first four experiments (A-D), the importance of the substitution pattern in the antranilic acid part of the AVAs was elucidated, i.e. the cinnamic acid part was the same within each experiment. The following three experiments (E-G) studied the influence of the substitution pattern in the cinnamic acid part of the compounds, i.e. the anthranilic acid part was the same within each experiment (due to lack of material, the experiment with the **3**-series was omitted). The inhibition capacity of Tranilast® and *trans*-resveratrol was tested in one additional experiment (H).

Since the enzyme activity in the buffer solution decreased with time, and to avoid autoxidation of the substrate each experiment was performed with freshly prepared enzyme and substrate solutions. Enzyme activity was measured as the amount of conjugated dienes formed from linoleic acid, expressed as area units. The inhibition was calculated as the enzyme activity difference between reaction with and without added test compound. Since the enzyme activity slightly differed between the experiments, inhibition was expressed as percentage of uninhibited sample within each experiment.

2.5. Statistics {#sec2.5}
---------------

Analysis of variance with Tukey\'s pairwise comparison (α = 0.05) was conducted using the software Minitab release 11.12 (Minitab Inc., State College, PA). Each experiment (A-H) was run separately with three replicates of each compound (except for **2s** in experiment G, which was run with two replicates). All comparisons were made within each experiment (A-H) since the conditions between experiments varied somewhat.

3. Results {#sec3}
==========

The lipoxygenase activity expressed as the relative amount of conjugated diene formed from linoleic acid in the presence of the test compounds is shown in [Figure 3](#fig3){ref-type="fig"}, where each letter (A-H) represents one experiment.Figure 3Products formed after lipoxygenase (LOX) activity on linoleic acid in the presence of avenanthramides, their corresponding cinnamic acids, Tranilast® or *trans*-resveratrol at 0.6 mM, expressed as percentage of controls (uninhibited samples). Each capital letter (A--H) represents one experiment. Error bars are given as coefficient of variation (CV) (except for **2s** in experiment G, which is given as the difference between the two replicates). Different superscript letters within each experiment A-H indicate significant differences (p \< 0.05) between the compounds tested.Figure 3

3.1. Structure-activity relationship of LOX inhibition {#sec3.1}
------------------------------------------------------

### 3.1.1. Influence of the anthranilic acid moiety {#sec3.1.1}

No significant difference in inhibition activity was found between the free cinnamic acids *p*-coumaric acid (**p**), ferulic acid (**f**), caffeic acid (**c**) and sinapic acid (**s**) and their corresponding AVAs ([Figure 3](#fig3){ref-type="fig"}, experiments A-D), except that **s** showed significantly higher inhibition than **3s**. Moreover, no differences were found within the **1**-, **2**- or **3**- series of AVAs (experiments A-D) except for **2f**, which exerted slightly higher inhibition than **3f,** and for **3s**, which showed lower inhibition than **1s** and **2s**. Compared to controls, the **p-**serie inhibited the LOX enzyme 0--30% (experiment A), the **f**-serie 0--20% (experiment B), the **c**-serie 50--70% (experiment C) and the **s-**serie 60--90% (experiment D). These results indicate that the anthranilic acid part of the avenanthramides was of minor importance for the inhibition.

### 3.1.2. Influence of the cinnamic acid moiety {#sec3.1.2}

Among the free cinnamic acids, caffeic (**c**) and sinapic (**s**) acids showed significant inhibition of LOX activity (60--90%) compared to the control, whereas *p*-coumaric (**p**) and ferulic (**f**) acids showed low or no inhibition ([Figure 3](#fig3){ref-type="fig"}, experiments A-D, E). The difference in inhibition between **c** and **s** was not significant (experiment E). A similar pattern was observed when the **1**-series of AVAs was studied (experiment F), i.e. **1c** and **1s** significantly inhibited LOX, whereas **1p** and **1f** did not. Again, there was no significant difference between the inhibition of **1c** and **1s**. The experiment with the **2**-series of avenanthramides showed that **2c** and **2s**, but also **2f**, had significant inhibitory effects and that all were significantly different in their activity, following the order **2s** \> **2c** \> **2f** (experiment G). The LOX activity was approximately 1.2 times higher in the sample with AVA **2p** compared with the control (experiment G). However, this was not observed in experiment A. The **3**-series could not be evaluated in this context, due to lack of material. However, from experiments A-D it was evident that **3c** and **3s** inhibited the LOX activity by 50--60% and **3p** inhibited it by around 30%, whereas no inhibitory activity was found for **3f**. This confirms that the cinnamic acid part of the AVAs, especially those containing caffeic and sinapic acids, was important for LOX inhibition.

### 3.1.3. Controls {#sec3.1.3}

*Trans*-resveratrol was an effective lipoxygenase inhibitor when present in the assay at a concentration of 0.60 mM, but Tranilast® was not ([Figure 3](#fig3){ref-type="fig"}, experiment H).

4. Discussion {#sec4}
=============

Although it has been shown that different phenols have LOX-inhibiting activity, the mechanisms involved have not been fully identified. In the active form of LOX, there is a ferric ion (Fe^3+^) at the active site. When linoleic acid is oxidised, the electron from the hydrogen atom is transferred to Fe^3+^ and its proton to a proton acceptor. The Fe^3+^ ion is thus reduced to a ferrous ion (Fe^2+^), rendering the enzyme inactive. The linoleic acid radical formed is re-arranged to a conjugated diene radical, which reacts with oxygen to form a peroxy radical. The peroxy radical reacts further with a proton and the electron from Fe^2+^ to form a hydroperoxide, Fe^2+^ is oxidised to Fe^3+^, the enzyme is thereby re-activated and the reaction can re-start with another linoleic acid ([@bib22]; [@bib20]). The mechanism of LOX inhibition can be explained in several ways, e.g. the inhibitor may scavenge the linoleic acid radicals formed, it may chelate or reduce the Fe^3+^ ion in the active site of the enzyme, or it may interact with the enzyme molecule.

Caffeic and sinapic acids and their corresponding AVAs were the most efficient inhibitors in the present study. These compounds are also strong antioxidants when tested in diphenylpicrylhydrazyl (DPPH) and non-enzymatic linoleic acid diene formation assays ([@bib2]; [@bib16]; [@bib31]; [@bib25]), both of which methods rely on a radical scavenging mechanism. The stronger antioxidation activity of **c** and **s** derivatives found was expected, as they are able to stabilise the phenolic radical formed better than **p** and **f** derivatives. However, if the enzymatic inhibition shown in the present study had been caused solely by radical scavenging, the **3**-series of AVAs would have been expected to be more active than the **2**-series, which in turn would have been more active than the **1**-series. This was not the case. Instead, it was found that there was no significant difference between the free cinnamic acids and their corresponding avenanthramides from the **1**-, **2**- and **3**-series ([Figure 3](#fig3){ref-type="fig"}, experiments A-D). We therefore suggest that chelation of the Fe^3+^ iron within the active site of the enzyme is important. However, it seems that a phenolic structure is also important, since the non-phenolic molecule Tranilast®, with the same basic skeleton as the AVAs ([Figure 1](#fig1){ref-type="fig"} a; [Table 1](#tbl1){ref-type="table"}), did not have any inhibitory properties under the test conditions. Tranilast® is an anti-inflammatory substance ([@bib28]; [@bib37]; [@bib12]), but the anti-inflammatory activity appears to be dependent on other mechanisms rather than through LOX inhibition. Other studies have also demonstrated that cinnamic acid analogues lacking the redox-active phenolic hydroxyl groups lose all LOX inhibitory activity and that radical scavenging is not sufficient to ensure efficient LOX inhibition ([@bib15]; [@bib51]).

We could not determine whether the inhibition observed in the present study was caused by an interaction between the phenolic compounds and the enzyme, since the initial velocity of product formation was not monitored. However, it is unlikely that the active compounds acted as competitive inhibitors, since their structures are very different from that of the substrate, i.e. linoleic acid. Nevertheless, other interactions between inhibitors and the enzyme may occur, as other studies have shown that caffeic acid derivatives exert both non-competitive ([@bib29]) and uncompetitive ([@bib49]) inhibition. These compounds have also been reported to inhibit the enzyme by chelating iron ions, thereby preventing catalysis ([@bib55]).

We recognize that high concentrations of AVAs have been used in our *in vitro* experiments. AVAs are bioavailable ([@bib8], [@bib7]; [@bib56]), but whether dietary AVAs at intake levels normally achieved through consumption of oat products exert LOX inhibitory activity *in vivo*, and thereby inhibit production of pro-inflammatory compounds, remains to be elucidated. In this context it may also be of importance to emphasize that the lipid content in groats of various oat cultivars is comparably high (49--135 g kg^−1^) and that LA and ALA comprise about 40% and 1%, respectively, of the fatty acids present ([@bib5]; [@bib48]). Theoretically, this may imply that oat derived LA, as a precursor to AA, could adversely affect the inflammatory processes and thereby counteract the possible protective effect of the avenanthramides. However, studies performed on healthy humans consuming a Western diet, have failed to show that additional dietary intake of LA is positively associated with pro-inflammation markers, such as e.g. interleukin-6 (Il-6), interleukin-1β (IL-1β), tumour necrosis factor (TNF-α) and c-reactive protein (CRP) in the plasma ([@bib24]; [@bib18]).

*In conclusion,* AVAs have been shown to possess anti-inflammatory properties and the present study provides *in vitro* findings suggesting that this could be due to inhibition of LOX activity. These findings, together with findings from previous studies on antioxidant activity ([@bib14]; [@bib2]; [@bib16]; [@bib31]; [@bib25]), may indicate that oat AVAs (especially the **c**-derivatives, as **s**-derivatives are not found in oats) can protect oat foods from rancidity development and contribute to anti-inflammatory effects in mammals. Further studies on foods and *in vivo* studies in mammals are needed to confirm this.

Declarations {#sec5}
============

Author contribution statement {#sec5.1}
-----------------------------

Rikard Landberg: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Wrote the paper.

Kerstin Sunnerheim: Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Lena H. Dimberg: Conceived and designed the experiments; Analyzed and interpreted the data; Wrote the paper.

Funding statement {#sec5.2}
-----------------

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interest statement {#sec5.3}
----------------------------

The authors declare no conflict of interest.

Additional information {#sec5.4}
----------------------

No additional information is available for this paper.

Dr Katharina Bratt and Dr Amelie Fagerlund are acknowledged for synthesis of the avenanthramides used in this study.

[^1]: **1:** anthranilic acid; **2:** 5-hydroxyanthranilic acid; **3:** 5-hydroxy-4-methoxyanthranilic acid; **p**: *p*-coumaric acid; **f**: ferulic acid; **c**: caffeic acid; **s**: sinapic acid.
